GA101 Associated with Better PFS In Phase III Trial Versus Rituximab in CLL
Two Phase II Ibrutinib Studies Presented to EHA Demonstrate Efficacy as a Monotherapy
FDA Approves Gilotrif Tablets in NSCLC, Boehringer Ingelheim’s First Approved Cancer Drug
Study: Ibrutinib Lowers IgM, Bone Marrow Disease Burden
ASCO Recommends Discussing Pharmacological Prevention
Elderly and Younger Patients Have Similar Outcomes Following Radioembolization
Cancer Genome Atlas Researchers Link Cell Metabolism Pathways To Disease Aggressiveness
Statistical Models Determine Stem-Cell Transplant Effectiveness
Phase II Elotuzumab Study Demonstrates 33 Months PFS
Ibrutinib Demonstrates 71% ORR In Phase Ib/II CLL and SLL Study
Biomarker Test Outperforms PSA and Gleason Score in Study
NCI CTEP Approved Trials For the Month of July
FDA Approves Implant For Breast Reconstruction
Trending Stories
- Right-wing provocateur Laura Loomer comes for FDA’s Vinay Prasad
- FY25 paylines drop to 4th percentile—a historic low—as NCI braces for Trump’s FY26 budget cuts
- In the Headlines: Is oncology ready to move away from animal testing?
- Oncologist biotech entrepreneur George Tidmarsh joins FDA as CDER director
His appointment came out of “proximity” to Makary and Bhattacharya - Will MCD tests revolutionize cancer screening? NCI begins enrollment in Vanguard “feasibility” trial to start finding out
- Robert Winn: If Medicaid gets massive cuts or goes away, where will these patients get care?
